A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS
A phase 2 trial of Trastuzumab brengitecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC is a phase 2 interventional study registered as NCT07264816 by Sichuan Baili Pharmaceutical Co., Ltd., with 80 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1, Pembrolizumab. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Pembrolizumab, Small-cell lung cancer.
- TrialA Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
Shares SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
Shares SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.